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HTLV-1-Associated Myelopathy (HAM/TSP) is a progressive neuroinflammatory disorder
for which no disease-modifying treatment exists. Modest clinical benefit from type I
interferons (IFN-α/β) in HAM/TSP contrasts with its recently identified IFN-inducible
gene signature. In addition, IFN-α treatment in vivo decreases proviral load and
immune activation in HAM/TSP, whereas IFN-β therapy decreases tax mRNA and
lymphoproliferation. We hypothesize this “IFN paradox” in HAM/TSP might be explained
by both cell type- and gene-specific effects of type I IFN in HTLV-1-associated
pathogenesis. Therefore, we analyzed ex vivo transcriptomes of CD4+ T cells, PBMCs
and whole blood in healthy controls, HTLV-1-infected individuals, and HAM/TSP patients.
First, we used a targeted approach, simultaneously quantifying HTLV-1 mRNA (HBZ,
Tax), proviral load and 42 host genes with known antiretroviral (anti-HIV) activity
in purified CD4+ T cells. This revealed two major clusters (“antiviral/protective” vs.
“proviral/deleterious”), as evidenced by significant negative (TRIM5/TRIM22/BST2) vs.
positive correlation (ISG15/PAF1/CDKN1A) with HTLV-1 viral markers and clinical status.
Surprisingly, we found a significant inversion of antiretroviral activity of host restriction
factors, as evidenced by opposite correlation to in vivo HIV-1 vs. HTLV-1 RNA levels. The
anti-HTLV-1 effect of antiviral cluster genes was significantly correlated to their adaptive
chimp/human evolution score, for both Tax mRNA and PVL. Six genes of the proposed
antiviral cluster underwent lentivirus-driven purifying selection during primate evolution
(TRIM5/TRIM22/BST2/APOBEC3F-G-H), underscoring the cross-retroviral evolutionary
imprint. Secondly, we examined the genome-wide type I IFN response in HAM/TSP
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patients, following short-term ex vivo culture of PBMCs with either IFN-α or IFN-β.
Microarray analysis evidenced 12 antiretroviral genes (including TRIM5α/TRIM22/BST2)
were significantly up-regulated by IFN-β, but not IFN-α, in HAM/TSP. This was
paralleled by a significant decrease in lymphoproliferation by IFN-β, but not IFN-
α treatment. Finally, using published ex vivo whole blood transcriptomic data of
independent cohorts, we validated the significant positive correlation between TRIM5,
TRIM22, and BST2 in HTLV-1-infected individuals and HAM/TSP patients, which was
independent of the HAM/TSP disease signature. In conclusion, our results provide ex
vivo mechanistic evidence for the observed immunovirological effect of in vivo IFN-
β treatment in HAM/TSP, reconcile an apparent IFN paradox in HTLV-1 research and
identify biomarkers/targets for a precision medicine approach.
Keywords: HTLV-1, HIV, retrovirus, evolution, interferon, neuroinflammation, multiple sclerosis, transcriptomics
BACKGROUND
Human T-cell Lymphotropic Virus-1 (HTLV-1), recently
renamed Human T-cell Leukemia Virus-1 due to its strong
oncogenic potential (Gallo et al., 2017; Tagaya and Gallo, 2017),
is also the causative agent of the debilitating neuroinflammatory
disorder, HTLV-1-Associated Myelopathy/Tropical Spastic
Paraparesis (HAM/TSP) (Osame et al., 1986). HAM/TSP
is associated with high HTLV-1 proviral load (PVL) and
transcriptional levels of retroviral regulatory genes, Tax and
HBZ (Saito et al., 2009). The pathogenesis of HAM/TSP
is complex (Bangham et al., 2015), and a proportion of
HTLV-1 asymptomatic carriers (AC) may present a PVL
and inflammatory profile similar to HAM/TSP patients but
do not develop clinical symptoms. It is unknown why 2–
3% of HTLV-1 infected patients develop HAM/TSP after
years of latent infection, but an interferon-inducible gene
signature has been identified in HAM/TSP and is absent in
AC (Tattermusch et al., 2012). However, type I interferon-
based clinical trials reported modest clinical benefit, as
well as antiviral (decreased PVL, Tax mRNA levels) and
immunomodulatory effects (decreased T-cell spontaneous
proliferation and activation), suggesting IFN-α and IFN-β may
hamper disease progression (Izumo et al., 1996; Oh et al., 2005).
To reconcile this apparent contradiction, we hypothesize specific
IFN-stimulated genes, e.g. antiviral effector genes, can exert
deleterious vs. protective roles in HAM/TSP, as we recently
suggested for B-cell expression of CD80 and CD86 (Menezes
et al., 2014).
In contrast to HTLV-1, several anti(retro)viral effector genes
have been classified as “restriction factors” (RFs) for HIV-1
infection, some of which are modulated by type I IFNs (Foster
et al., 2017). We have previously compiled and validated a real-
time PCR-array of 42 well-characterized RFs with suppressive
activity against HIV-1 (Neil et al., 2008; Abdel-Mohsen et al.,
2013; Raposo et al., 2013a,b, 2014), including APOBECs,
TRIMs, and BST2/Tetherin.. Enhanced HIV-1 infection upon
siRNA-mediated silencing in neuroblasts illustrates the relevance
of TRIM5α and TRIM22 in neuroinfection (Singh et al.,
2014).
To assess the role of antiretroviral genes in HAM/TSP
pathogenesis, we determined transcriptional levels of 42 RFs
and regulatory HTLV-1 genes Tax and HBZ in CD4+ T
cells from HTLV-1 patients. We identified a strong negative
association between expression of HTLV-1 Tax and a cluster
of RFs, including TRIM5α/TRIM22/BST2. Genome-wide
transcriptomic analysis of HAM/TSP patients showed a
significant and distinct up-regulation of RFs after ex vivo
exposure to IFN-β, but not IFN-α. These results provide
mechanistic evidence for the immunovirological impact of
IFN-β therapy observed in vivo in HAM/TSP patients and pave
the way to an evidence-based precision medicine approach to
this neuroinflammatory disorder.
PATIENTS AND METHODS
All participants signed a written informed consent in accordance
with the Declaration of Helsinki, approved by the University
Institutional Review Boards of USP (#0855/08) and CPqGM-
FIOCRUZ (#022/03) before inclusion in the study. Ex vivo
analysis of antiretroviral restriction factors was conducted in
a cohort of 18 individuals (7 HAM/TSP, 6 HTLV-1-infected
asymptomatic carriers (AC) and 5 age- and gender-matched
HTLV-1-negative healthy controls (HC)), enrolled at the HTLV-
1 Outpatient Clinic at the University of Sao Paulo (USP), Brazil.
The second cohort (lymphoproliferation/microarray analysis)
consisted of 10 HAM/TSP patients, followed at the Bahiana
School of Medicine and Public Health HTLV reference center
in Salvador-Bahia, Brazil. Validation of transcriptomic findings
was performed in a third, published cohort (London, UK).
Demographic and clinical data of all cohorts are detailed in
Table 1. Clinical status was determined based on WHO criteria
for HTLV-1 associated diseases (Osame, 1990). None of the
HAM/TSP patients had received prior IFN-based therapy. Blood
samples were obtained and processed with Ficoll-Paque PLUS
(Amersham Pharmacia Biotech, Uppsala, Sweden) gradient
centrifugation and peripheral-blood mononuclear cells (PBMC)
were isolated and either cryopreserved in 10 % DMSO in FBS
(RF analysis) or used for short-term ex vivo culture (48 h for
microarray analysis, 96 h for lymphoproliferation), in the absence
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TABLE 1 | Demographic and clinical data of 3 HTLV-1 cohorts.










Gender 1M/4F 1M/5F 2M/5F
PVL (median, ±
SD)
N/A 7.6 ± 151.5 181.0 ± 134.5
Tax mRNA
(median, ± SD)
N/A 0.02 ± 0.02 0.68 ± 0.77
HBZ mRNA
(median, ± SD)




















49(46–71) 47(38–62) 54(49–62) 63(44–74)
Gender 4M/4F 0M/17F 4M/6F
PVL (median,
IQR)




or presence of 1,000 IU/ml clinical grade IFN-α (gift of Blausiegel
Ltda., Sao Paulo-Brazil) or IFN-β (gift of Dr. Brassat, Toulouse-
France), as previously described (Moens et al., 2012a; Dierckx
et al., 2017).
Proviral Load and mRNA Assessment
Total DNA and RNA were extracted from enriched CD4+ T cells
using a commercial kit (Qiagen GmbH, Hilden Germany) and
cDNAwas generated using Superscript VILO cDNA synthesis kit
(Invitrogen) following the manufacturer’s instructions. HTLV-1
proviral load absolute quantification was performed as previously
described (Dehee et al., 2002), normalized to human albumin
gene. Samples were assayed in duplicate. HTLV-1 proviral load
was calculated as follows: copy number of HTLV-1 per 1,000
CD4+ T cells = (copy number of HTLV-1)/(copy number of
albumin)× 2× 1,000 cells.
Transcription levels of Tax and HBZ were measured
as previously described (Saito et al., 2009), using
housekeeping gene Ubiquitin C (Life Technologies assay
ID# Hs00824723_m1) to calculate tax and HBZ 2−1Ct
relative expression. Relative quantification of 42 RFs using
mRNA from CD4+ T cells from 13 HTLV-1-infected patients
and 5 uninfected healthy controls was performed using
custom-made TaqMan R© Low Density Arrays previously
described (Abdel-Mohsen et al., 2013)(Applied Biosystems,
Foster City, CA). RF gene descriptions are given in
Table 2.
Microarray Analysis
Total RNA extraction (RNeasy kit, QIAGEN, Venlo, the
Netherlands) and Whole Genome microarray analysis (HuGene
1.0 ST array, Affymetrix, Santa Clara, CA) were performed
according to the manufacturers’ specifications. Data were
analyzed using the Bioconductor limma package. Microarray
data used in this study are available at Gene Expression Omnibus
under GEO accession number GSE82160 (Brazilian HTLV-1
cohort), GSE29333 (UK HTLV-1 cohort, Tattermusch et al.) and
GSE18233 (Swiss HIV cohort, Rotger et al., 2010).
Enrichment and Evolutionary Analysis
Genome-wide enrichment analysis was performed using a
modified Fisher’s test, considering the total number of annotated
genes for which transcripts were detectable by microarray (n
= 22,370), followed by stringent FDR (Benjamini–Hochberg)
correction. Data and full methodology on human candidate
retroviral restriction factors and chimp/human cross-species
adaptive evolution and purifying selection during primate
evolution are detailed in (Osame, 1990; Singh et al., 2014). In
brief, measurements of cross-species adaptive evolution used
the McDonald-Kreitman value to compare human sequence to
chimpanzee in a set of 15,052 protein-coding genes (Singh et al.,
2014) and purifying selection during primate evolution was
measured using the proportion of nonsynonymous (KA) over
synonymous (KS) substitutions per site in five primates (human,
chimpanzee, orangutan, rhesus, and common marmoset) in a
set of 140 candidate genes selected for their relationship to HIV
pathogenesis (Osame, 1990).
Statistical Analysis
Statistical analysis was performed using GraphPad Prism
software (GraphPad Software, version 6 and 7, San Diego, CA).
Non-parametric statistical tests (Mann–Whitney,Wilcoxon tests,
and Spearman correlation) were used for patient data, with
Bonferroni correction for multiple comparisons between RFs,
PVL and tax/HBZmRNA levels. Transcriptome-wide correlation
of mRNA expression levels with either set point viral load (HIV-
1) or TRIM5 (HTLV-1) mRNA expression was calculated using
Spearman’s correlation, followed by FDR correction for multiple
testing.
RESULTS
Antiretroviral RFs Separate in Two Major
Clusters, Positively and Negatively
Associated With HTLV-1 Virological and
Clinical Status
Based on a previously defined subset of host genes with
significant anti-HIV activity (Abdel-Mohsen et al., 2013), we
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TABLE 2 | List of 42 antiretroviral genes measured in CD4+ T cells.
Target Information NCBI Gene Description
APOBEC3A-H Apolipoprotein B mRNA editing enzyme, catalytic polipeptide-like 3
BST2/theterin Bone Marrow Stromal cell antigen 2
SLFN11 Schlafen family member 11
TRIM5α, TRIM11, TRIM21, TRIM22, TRIM26, TRIM28, TRIM32 Tripartite motif family
CPSF6 Cleavage and Polyadenylation Specific Factor 6
SAMHD1 SAM domain and HD domain 1
PML Promyelocytic Leukemia protein
RNF114 Ring Finger Protein 114
Trex1 Three Prime Repair Exonuclease 1
RPRD2 Regulation of nuclear Pre-mRNA Domain containing 2
CHFR Checkpoint with forkhead and ring finger domains, E3 ubiquitin protein ligase
ISG15 ISG15 ubiquitin-like modifier
EIF2AK2/PKR Eukaryotic translation initiation factor 2-alpha kinase 2
CTR9/PAF1/RTF1 CTR9, PAF1, RTF1/RNA polymerase II complex component
IFITM family (3 members) Interferon induced transmembrane protein
RSAD2 (viperin) Radical S-adenosyl methionine domain containing 2
MOV10 Moloney leukemia virus 10, homolog
HERC5 HECT domain and RLD 5
MX2 MX dynamin like GTPase 2
CDKN1A Cyclin-dependent kinase inhibitor 1A
BRD4 Bromodomain containing 4
RNASEL Ribonuclease L (2′,5′-oligoisoadenylate synthetase-dependent)
CH25H Cholesterol 25-Hydroxylase
LGALS3BP Lectin, Galactoside binding Soluble 3 Binding Protein
CNP 2′,3′-cyclic nucleotide 3′ phosphodiesterase
IFI16 Interferon gamma Inducible protein 16
used a custom-made array to quantify the transcriptional levels
of 42 RFs (listed in Table 2) in peripheral CD4+ T cells from
HTLV-1 infected patients or healthy controls. We compared the
gene expression profiles of 13 HTLV-1-infected patients (6 AC,
7 HAM/TSP) and 5 uninfected subjects using cluster analysis.
As evident from Figure 1A, two major RF subsets appeared as
separate clusters. First, a minor cluster of RFs (CDKN1A/ISG15
and PAF1) positively correlates with biomarkers of HTLV-
1 disease (PVL, mRNA levels of Tax and HBZ, as well as
clinical status, box Figure 1A). Second, the largest cluster of
RFs was found to correlate negatively with HTLV-1 biomarkers
(Figure 1A). Within this large cluster, negative correlations
between the expression levels of Tax and TRIM5α (r=−0.86; p=
0.0084), TRIM22 (r =−0.81; p= 0.0336), BST2 (r =−0.85; p=
0.0126), and RNASEL (r = −0.83; p = 0.021) were statistically
significant after stringent Bonferroni correction (Figure 1B).
Conversely, cyclin-dependent kinase inhibitor 1A (CDKN1A,
also known as p21), a regulator of cell-cycle progression, was
positively associated with HTLV-1 proviral load (r = 0.84; p
= 0.042) (Figure 1C). Surprisingly, these ex vivo correlations
recapitulate the in vivo findings of IFN-β treatment in an
immunovirological trial in HAM/TSP, in which IFN-β was
found to significantly decrease both tax mRNA levels and
lymphoproliferation (Oh et al., 2005), but not PVL. In contrast,
in vivo IFN-α treatment of HAM/TSP patients was found to
decrease PVL and immune activation (Izumo et al., 1996).
Therefore, we investigated if IFN-α/β might differentially affect
lymphoproliferation and genome-wide expression profiles in
HAM/TSP.
Ex Vivo Lymphoproliferation Is Significantly
Down-Regulated by IFN-β, but Not IFN-α in
HAM/TSP
We found that lymphoproliferation was significantly inhibited by
IFN-β (p < 0.01), but not by IFN-α (Figure 2) This differential
effect was not due to a defect in IFN-α bioactivity, since both
IFNs displayed equal antiviral activity in a standardized Vesicular
Stomatitis Virus (VSV) bioassay (Dierckx et al., 2017). This effect
was specific for HAM/TSP, since no significant IFN-induced
antiproliferative effect was observed in both healthy controls
(Figure 2) and HTLV-1-infected carriers (data not shown).
Genome-Wide Analysis Identifies Selective
Up-Regulation of RFs by IFN-β, but Not
IFN-α, in HAM/TSP
Since RFs can be IFN-regulated, we used microarray analysis
to assess whether the proviral and antiviral clusters might be
selectively up- or down-regulated by either IFN-α or IFN-β, the
two IFN subtypes previously used in HAM/TSP trials (Izumo
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FIGURE 1 | Association between host restriction factors (RFs) expression, HTLV-1 virological parameters and clinical status of HTLV-1 infected individuals. (A)
Analysis of mRNA levels of 42 RFs, Tax/HBZ and HTLV-1 proviral load (PVL) in CD4+ T cells from 6 asymptomatic carriers (AC), 7 HAM/TSP patients and 5 healthy
donors (HD). Expression of host RFs was quantified by TLDA, results were clustered according to Spearman’s correlation and shown as heatmap (red = negative,
green = positive). The boxed cluster indicates a minor subset of “proviral” RFs (CDKN1A, ISG15) clustering with HTLV-1 PVL, Tax mRNA, HBZ mRNA, and clinical
status (HD/AC/HAM), whereas the majority of RFs forms a large “antiviral” cluster. A subset of antiviral RFs (TRIM5α, TRIM22, BST2, and RNASEL) with statistically
significant negative correlation to tax mRNA are highlighted in red. (B) Correlation between TRIM5α, TRIM22, BST2, RNASEL, and tax mRNA (C) Correlation between
CDKN1A and tax mRNA in HTLV-1-infected individuals (AC n = 6, HAM n = 7).
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FIGURE 2 | Ex vivo lymphoproliferation is significantly down-regulated by
IFN-β, but not IFN-α in HAM/TSP. Spontaneous lymphoproliferation was
measured by [3H]-thymidine incorporation, as previously described Moens
et al. (2012a). The effect of IFN-α and IFN-β (1000 IU/ml) upon ex vivo
lymphoproliferation was determined in healthy controls (HC, n = 11) and
HAM/TSP patients (n = 10). **p < 0.01.
et al., 1996; Oh et al., 2005). As shown in Figure 3A, genome-
wide analysis identified 12/42 RFs (including TRIM5α, TRIM22,
and BST2) were significantly up-regulated by IFN-β (n = 5,
enrichment p < 0.0001), vs. 0/42 by IFN-α treatment (n = 6,
p > 0.05) during short-term (48 h) ex vivo culture of PBMC
from HAM/TSP patients. In a striking parallel to our results in
CD4+ T cells, where TRIM5 displayed the strongest negative
correlation to Tax mRNA, TRIM5 was also identified as the top
IFN-β-induced gene among the significant genes (p= 0.0009).
Genome-Wide Analysis Identifies a
Strongly Co-regulated
TRIM5α/TRIM22/BST2 Subset in HTLV-1
Infection, Independent of the HAM/TSP
Disease Signature
To validate our findings, we analyzed published ex vivo whole
blood transcriptomes in an additional HTLV-1-infected cohort
(Tattermusch et al.; detailed in Table 1) (Osame et al., 1986).
As shown in Figure 3B, significant positive correlations were
confirmed between TRIM5α/TRIM22 (p = 0.005, r = 0.50) and
TRIM5α/BST2 (p < 0.001, r = 0.67) in both HTLV-1-infected
AC (n = 17) and HAM/TSP patients (n = 10). Of note, TRIM5α
mRNA expression was not significantly correlated to IFITM1
mRNA levels (data not shown), which is the only RF (among 42
studied herein) that is present in the HAM/TSP disease signature.
RFs Correlate Oppositely to in Vivo
Retroviral RNA Levels in Untreated HTLV-1
vs. HIV-1 Infection
Surprisingly, the “proviral/deleterious” gene cluster identified
by its strong positive correlation to HTLV-1 RNA levels and
PVL contains the RFs previously demonstrated to exert a
robust protective anti-HIV-1 effect in vivo and in vitro, namely
CDKN1A, SLFN11, PAF1, and ISG15 (Telenti, 2005; Ortiz et al.,
2009; McLaren et al., 2015; Nozuma et al., 2017). Therefore, we
performed a pairwise analysis of correlation to in vivo RNA levels
in both retroviral infections, using our HTLV-1 data (Figure 1A)
and data from the Swiss HIV cohort (Rotger et al., 2010) by
calculating transcriptome-wide correlation of viral load set point
to each separate gene, followed by FDR correction. As shown
in Figures 4A,B, a striking opposite effect can be observed for
the “proviral” vs. “antiviral” clusters. HTLV-1 “antiviral” cluster
genes show significantly increased (higher R-values) correlation
to HIV-1 in vivo RNA levels (p < 0.0001, Wilcoxon signed rank
test, Figure 4A). The reverse phenomenon can be observed for
the HTLV-1 “proviral” cluster genes, showing a tendency for
decreased (lower R-values) correlation to HIV-1 in vivo RNA
levels (p= 0.06, Wilcoxon signed rank test, Figure 4B).
Lentivirus-Driven Primate Evolution Has
Shaped Antiretroviral Activity in Untreated
HTLV-1 Infection
Lentivirus infections, to which HIV and its ancestral SIV belong,
have had a pronounced effect upon primate evolution (Telenti,
2005), whereas no similar evidence exists for deltaretroviruses,
such as HTLV or PTLV. As shown in Figure 5, the antiviral
RF cluster we identified for HTLV-1 is strongly selected
during recent primate evolution, as measured by both cross-
species adaptive evolution between chimpanzees and humans
(Figures 5A,B) and purifying selection throughout primate
evolution (Figure 5C). Among the 42 anti-HIV RFs selected in
this study, ten (TRIM5, APOBEC3A-B-C-F-G, IFI16, HERC5,
EIF2AK2, and MX2) were found to display chimp/human
adaptive evolution, as described by McLaren et al. (2015). The
anti-HTLV-1 effect (measured as R2 to represent effect size)
of these 10 genes was significantly correlated to their adaptive
evolution score, for both Tax mRNA (r = 0.86, p = 0.0013,
Figure 5A) and PVL (r = 0.78, p = 0.0073, Figure 5B). In
agreement with our results in Figures 1A,B, the effect size was
greater for TaxmRNA (Figure 5A—range 0.1–0.74) than for PVL
(Figure 5B—range 0.0–0.23), underscoring the putative role of
these RFs in viral replication, rather than clonal expansion. Only
six genes of the proposed “antiviral” cluster (TRIM5, TRIM22,
and BST2, as well as APOBEC3F-G-H) underwent lentivirus-
driven purifying selection during primate evolution (Ortiz et al.,
2009), measured as KA/KS. In addition, these six HTLV-1-
correlated genes underwent a significantly stronger selection
during primate evolution, as compared to all other lentivirus-
selected primate genes (n= 134, p< 0.0001,Mann–Whitney test,
Figure 5C).
DISCUSSION
The striking negative association between mRNA levels of Tax
and RFs TRIM5α, TRIM22, BST2, and RNASEL, despite the
small number of participants in the study, suggests that these
RFs may represent important mechanisms of defense against
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FIGURE 3 | Genome-wide analysis of PBMCs from HAM/TSP patients of RFs after ex vivo treatment with type I interferons. (A) Microarray analysis to determine
genes significantly up- or down-regulated after 48 h ex vivo treatment of PBMCs from HAM/TSP patients with 1000 IU/ml IFN-β (n = 5), upper right corner pie-chart or
IFN-α (n = 6), lower right corner pie-chart. RFs were significantly enriched among IFN-β-regulated, (upper left corner, genome-wide enrichment p < 0.0001), but not
IFN-α-regulated (lower left corner, p > 0.05) genes. A total of 22370 genes were analyzed. (B) Reanalysis of published ex vivo whole blood transcriptomes from an
independent HTLV-1 UK cohort (Tattermusch et al., 2012). Correlation between TRIM5α and TRIM22/BST2 in both HTLV-1-infected AC (n = 17) and HAM/TSP
patients (n = 10).
HTLV-1 infection and/or neuroinflammation. Our hypothesized
antiviral activity of TRIM5 against HTLV-1 is supported by the
recent findings of Nozuma et al. demonstrating a significant
association between TRIM5 R136Q polymorphism and lower
PVL, specific to HAM/TSP patients (Nozuma et al., 2017).
Strikingly, polymorphisms in TRIM5, TRIM22, and BST2, but
not APOBECs or TREX1 were significantly associated to another
neuroinflammatory disorder, multiple sclerosis (Nexo et al.,
2013). Conversely, the apparent proviral effect of PAF-1, ISG15,
and CDKN1A are in agreement with the recently demonstrated
IFN-inducible HAM/TSP disease signature (Tattermusch et al.,
2012). Moreover, the robustness of the antiviral and proviral
clusters we identified in this study indicates they represent
plausible candidate biomarkers for future HAM/TSP clinical
trials. In agreement with Saito et al., who demonstrated a
positive correlation between HBZ mRNA levels and HAM/TSP
disease severity (Saito et al., 2009), our cluster analysis shows
the strongest association between HBZ and clinical status
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FIGURE 4 | Restriction factors correlate oppositely to in vivo retroviral RNA levels in untreated HTLV-1 vs. HIV-1 infection. A pairwise analysis was performed for RFs
in antiviral and proviral clusters, by correlating to in vivo RNA levels in both retroviral infections, using HTLV-1 data from this study (Figure 1A) and data from the Swiss
HIV cohort (Rotger et al., 2010). Out of 42 RFs, 40 were matched to unique transcripts in HIV-1 microarray data, followed by calculating transcriptome-wide
correlation of viral load set point to each separate gene, using stringent FDR (Benjamini-Hochberg) correction. (A) HTLV-1 “antiviral” cluster genes show significantly
increased (positive) correlation to HIV-1 in vivo RNA levels (****p < 0.0001, Wilcoxon signed rank test, n = 35). (B) HTLV-1 “proviral” cluster genes show a tendency
for decreased (positive) correlation to HIV-1 in vivo RNA levels (p = 0.06, Wilcoxon signed rank test, n = 5).
(Figure 1A). However, no RFs were significantly correlated to
HBZ mRNA levels after correction for multiple testing, in
contrast to tax mRNA levels (Figure 1B). This might be due
to post-transcriptional regulation of HBZ mRNA vs. protein
levels, as Baratella et al. recently demonstrated cytoplasmatic
HBZ protein as a biomarker able to discriminate between AC
and HAM/TSP (Baratella et al., 2017). Due to their significant
association with all currently used surrogate markers (PVL, Tax,
andHBZmRNAs), as well as clinical status, antiviral and proviral
clusters are likely to reflect positive vs. negative therapeutic
outcomes, respectively. Therefore, our results help explain
the “IFN paradox” in HAM/TSP, by reconciling apparently
conflicting data in the literature, namely the existence of an
interferon-inducible disease signature and the demonstrated
beneficial therapeutic effects of type I interferons, both IFN-α and
β in HAM/TSP (Izumo et al., 1996; Oh et al., 2005).
In addition, our study also reveals striking differences
between these two widely used IFN subtypes. First, a significant
antiproliferative effect of β and not α was observed in HAM/TSP
patients, corroborating our recent findings in ATL (Dierckx
et al., 2017) and revealing a surprising similarity between
these two highly distinct HTLV-1-associated pathologies. On
the other hand, our study also reveals another parallel between
neuroinflammatory disorders HAM/TSP and multiple sclerosis,
namely their unique sensitivity to IFN-β over IFN-α. Of note, our
results provide mechanistic evidence for the previously described
immunovirological and clinical impact observed in vivo with
IFN-β therapy in HAM/TSP patients, in an open-label trial (Oh
et al., 2005), as well as two case reports with remarkable clinical
response (Costa et al., 2012; Viana et al., 2014). This superior
antiproliferative effect of IFN-β in HAM/TSP, as compared
to IFN-α, parallels our findings in the other major HTLV-1-
associated disease, Adult T-cell Leukemia (Dierckx et al., 2017).
Surprisingly, the “proviral/deleterious” gene cluster, identified
by its strong positive correlation to HTLV-1 RNA levels and
PVL, contains the RFs previously demonstrated to exert the
strongest protective anti-HIV-1 effect in vivo and in vitro. Thus,
p21 (CDKN1A), schlafen 11 (SLFN11), and PAF1 were strongly
associated with reduced CD4+ T cell-associated HIV RNA
during antiretroviral treatment (Abdel-Mohsen et al., 2015).
SLFN11 was also identified as overexpressed in HIV-positive
“elite controllers” (Abdel-Mohsen et al., 2013), who maintain
undetectable viral load, even in the absence of antiretroviral
treatment. PAF1 was identified by a genome-wide screen for HIV
RFs (Liu et al., 2011) and restricts HIV-1, HIV-2, and SIV in vitro.
Finally, CDKN1A was demonstrated as a robust antiviral effect
against HIV-1 replication in vitro, by different groups (Leng et al.,
2014; Farberov et al., 2015).
With up to eight percent of the human genome of retroviral
origin, the importance of retroviruses for the evolution of
susceptible host organisms cannot be overestimated (Ortiz et al.,
2009; Lascano et al., 2015). Over millions of years, Lentivirus
infections (retroviruses including HIV and ancestral SIV) have
had a pronounced effect upon primate evolution (Ortiz et al.,
2009). Yet, no evidence exists for deltaretroviruses (including
HTLV and PTLV). Using two different quantitative approaches,
i.e., measuring chimp/human cross-species adaptive evolution
(Figures 5A,B) and purifying selection throughout primate
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FIGURE 5 | Lentivirus-driven primate evolution has shaped antiretroviral activity in untreated HTLV-1 infection. The antiviral RF cluster is strongly selected during
recent primate evolution, as measured by both cross-species adaptive evolution between chimpanzees and humans and purifying selection throughout primate
evolution. (A,B) Among the 42 anti-HIV RFs selected in this study, 10 were found to display chimpanzee/human cross-species adaptive evolution (McLaren et al.,
2015). The anti-HTLV-1 effect (measured as R2) of these 10 genes was significantly correlated to their adaptive evolution score, for both Tax mRNA (r = 0.86, p =
0.0013) and PVL (r = 0.78, p = 0.0073). (C) Six genes of the proposed antiviral cluster underwent lentivirus-driven purifying selection (measured as KA/KS, Ortiz
et al., 2009) during primate evolution, which was significantly increased vs. all other lentivirus-selected primate genes (n = 134, ****p < 0.0001, Mann–Whitney test).
evolution (Figure 5C), we found that the antiviral RF cluster
we identified for HTLV-1 was under strong purifying selection
during recent primate evolution. Our preselection of a small
number of candidate RFs, by virtue of their proven antiviral
effect against HIV-1, is an obvious limitation of the first part
of our study, focusing on purified CD4+ cells. However, we
confirm the unique TRIM5/TRIM22/BST2 antiviral cluster by
two independent unbiased methods, i.e., PBMC transcriptomics
and genome-wide evolutionary analysis of protein-coding genes.
By comparing the only two pathogenic human retroviruses, we
found striking differences in in vivo correlations of “candidate”
RFs to retroviral RNA levels, as an indirect measure of their
possible anti-HIV and anti-HTLV-1 activity. Although some
antiviral effector molecules such as cGAS exhibit “panviral”
activity (Schoggins et al., 2014), our results argue against
“panretroviral” restriction factors in the human setting. Very
few host genes, such as CIITA and PKR (also known as
EIF2AK2), have been formally demonstrated to restrict both
HIV-1 and HTLV-1 replication in vitro (Schoggins et al., 2011;
Tosi et al., 2011; Cachat et al., 2013; Kinpara et al., 2013;
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Forlani et al., 2016). Interestingly, CIITA interacts and cooperates
with TRIM22 in restricting replication of HIV-1 (Forlani et al.,
2017). However, CIITA is unique among RFs because it is
transcriptionally upregulated by IFN-gamma but downregulated
by IFN-β (Lu et al., 1995). In contrast, IFN-α strongly upregulates
PKR/EIF2AK2 in HTLV-1-infected cells but does not decrease
Tax or Hbz mRNA (Moens et al., 2012b; Cachat et al., 2013;
Kinpara et al., 2013). Thus, CIITA and PKR are unlikely
candidates for the IFN-β-mediated antiviral and antiproliferative
effect we observed ex vivo and in vitro in HAM/TSP patients.
Unfortunately, high-throughput in vitro analysis of RFs, such as
performed by Schoggins et al. for HIV-1 and several other viruses,
are lacking for HTLV-1 (Schoggins et al., 2011). Based on our
previous demonstration of a 1000-fold difference in HIV-1 vs.
HTLV-1 antiviral effect in co-infected MT-4 cells (Moens et al.,
2012b) we anticipate strong differences might be observed for in
vitro HTLV-1 vs. HIV-1 restriction pathways. As a final layer of
complexity, HIV-1 also displays striking discrepancies between
in vivo and ex vivo RF antiviral activity (Rotger et al., 2010;
Schoggins et al., 2014). Therefore, we believe the term “restriction
factors” should be used with caution in human retrovirology.
“Antiviral effector genes” might be a more precise term, if defined
within a precise context, i.e., depending on cell type, virus and
upstream regulators such as IFN subtypes. Regarding cell type-
specificity, TRIM5α and TRIM22 expression at both mRNA and
protein level has been shown to predominate in CD4+ T cells,
as compared to other mononuclear cell types (Singh et al., 2014),
which explains the strong agreement between our RF analysis in
CD4+ T cells and IFN response in PBMCs, as well as whole blood
analysis from UK cohort participants (Tattermusch et al., 2012).
Mechanistically, both the antiviral vs. “proviral” effects of
TRIM5, CDKN1A, and ISG15 might also be explained by
broader cellular processes, outside the narrow definition of
RFs. TRIM5 is an intracellular protein that exerts its protective
effect by disrupting the retroviral capsid as it transports viral
nucleic acid into the nucleus. In addition, innate immune
signaling might contribute to TRIM5-mediated restriction.
Lascano et al. have shown that activation of innate immune
signaling is conserved among primate and carnivore TRIM5
orthologs and that such activity is required for TRIM5-
mediated restriction activity (Lascano et al., 2015). CDKN1A
upregulation by Tax might shorten G1 phase by promoting
formation of stable kinase complexes, contributing to cell-
cycle progression (Kehn et al., 2004) and proliferation of
infected clones. Regarding ISG15, our group has recently
demonstrated its anti-inflammatory extracellular cytokine-like
activity, through monocyte-specific induction of IL-10 (Dos
Santos et al., 2018). However, recent data reveal an unexpected
IL-10-induced proliferative switch in HAM/TSP-derived HTLV-
1-infected T-cell lines (Sawada et al., 2017). Therefore, ISG15
inducing IL-10 and hence triggering lymphoproliferation might
represent, at least in part, a molecular mechanism for the
putative “proviral” role of ISG15 in HAM/TSP. Integrating
the data from Tattermusch et al. (2012), Dos Santos et al.
(2018), Sawada et al. (2017) and this study, we hypothesize
that an “IFN-beta like/TRIM5” gene signature vs. a “non-
IFN-beta like/ISG15” gene signature might be predictive of
HAM/TSP disease progression, as well as of therapeutic outcome
with immunomodulatory and/or antiproliferative drugs (IFNs,
glucocorticoids and others).
In conclusion, our integrated ex vivo approach reveals
that antiretroviral genes in HTLV-1 infection and HAM/TSP
cluster in two distinct “proviral/antiviral” classes, of which the
TRIM5α/TRIM22/BST2 antiviral subset, selected during recent
primate evolution, is selectively up-regulated by IFN-β signaling
in HAM/TSP. Our results thus provide ex vivo mechanistic
evidence for the observed in vivo immunovirological effect
of IFN-β treatment in HAM/TSP and identify biomarkers as
well as possible therapeutic targets for a precision medicine
approach. Finally, a protective antiviral and IFN-inducible
TRIM5α/TRIM22/BST2 gene cluster, independent of the
HAM/TSP IFN-inducible disease signature, reconciles the
apparent IFN paradox in HTLV-1 research and confirms
type I IFN as a two-edged sword in human health and
disease.
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